Ionis Pharmaceuticals Inc (IONS.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|72||1991||Chairman of the Board, President, Chief Executive Officer|
|55||2013||Chief Financial Officer, Senior Vice President - Finance|
|63||2013||Chief Operating Officer, Corporate Secretary, Director|
|43||2016||Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary|
|60||2006||Senior Vice President - Antisense Research|
- BRIEF-Akcea And Ionis Complete Licensing Transaction To Commercialize Inotersen
- UPDATE 1-Ionis may get up to $300 mln in licensing deal with AstraZeneca
- Ionis to get up to $300 mln from licensing deal with AstraZeneca
- BRIEF-Ionis And AstraZeneca Advance New Drug For NASH
- UPDATE 2-Pfizer's rare heart disease drug succeeds in late-stage study